Ask about this productRelated genes to: ORC6L antibody
- Gene:
- ORC6 NIH gene
- Name:
- origin recognition complex subunit 6
- Previous symbol:
- ORC6L
- Synonyms:
- -
- Chromosome:
- 16q11.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-02-14
- Date modifiied:
- 2016-10-05
Related products to: ORC6L antibody
Related articles to: ORC6L antibody
- With the application of precise clinical interventions in tumor treatment, it is of great value to explore novel biomarkers and their underlying molecular mechanisms. In this paper, we firstly explored the prognostic, immunological features, functions, and potential mechanisms of ORC6 in kidney renal clear cell carcinoma (KIRC) via single-cell and bulk RNA sequencing. Single-cell and bulk RNA sequencing data related to ORC6 data in KIRC were acquired from shared online databases. Spearman correlation analyses were carried out to investigate the relationships between ORC6 expression and interested targets, including tumor mutation burden (TMB), tumor microenvironment, and immunotherapy responses. Besides, the expression pattern of ORC6 and its role in KIRC were verified in vitro experiments. Also, the potential mechanisms and regulatory upstream of ORC6 in KIRC were explored. ORC6 was up-regulated in KIRC samples compared with normal tissues, validated by PCR analyses of KIRC tissues and cell lines (p < 0.05). Single-cell RNA sequencing analysis showed that ORC6 was mainly expressed in immune T cells. Survival and Cox regression analysis showed ORC6 had prognostic values in KIRC (p < 0.05). Correlation analysis revealed ORC6 was strongly correlated with immunity and immunotherapy sensitivity (p < 0.05). Further experiments in vitro indicated that ORC6 could regulate the cell proliferation/apoptosis of KIRC. Finally, a putative long non-coding RNA (LncRNA)/RNA binding protein (RBP)/ORC6 regulatory network was identified to explore ORC6-related potential upstream regulatory mechanisms in KIRC. In conclusion, ORC6 might play oncogenic roles in KIRC and regulate cell proliferation/apoptosis in KIRC. Furthermore, ORC6 showed significant associations with immunity and potential immunotherapy sensitivity. These findings provided a foundation for future studies evaluating the clinical significance of ORC6 in KIRC. - Source: PubMed
Yu YangZhai JingLiu ShiweiWang YiDing Guanxiong - The origin recognition complex (ORC) is a DNA-binding complex composed of six subunits involved in DNA replication in cancer cells. The prognostic and immunological implications of ORC6 in lung adenocarcinoma (LUAD) are not yet clear. This study utilizes multiple databases (such as TCGA, GEO, GTEx, etc.) to investigate the potential significance of ORC6 in LUAD. The results show that high ORC6 expression is associated with advanced disease and poorer prognosis and is involved in biological processes such as cell cycle regulation, DNA replication, and signal transduction. The expression of ORC6 correlates negatively with the infiltration of CD4+ and CD8+ T cells but positively with the infiltration of cancer-associated fibroblasts and endothelial cells. Additionally, a positive correlation between ORC6 and immunosuppression-related genes (such as LAG3 and PDCD1) was found. Validation of ORC6 expression was conducted through qRT-PCR, western blotting, and immunofluorescence, indicating its potential diagnostic, prognostic, and therapeutic value in LUAD. - Source: PubMed
Publication date: 2026/03/23
Huang XinFeng DongfengTian YanhuaZhang XuLi YishuaiHe YejuLiu Yang - Cisplatin-based chemotherapy is a cornerstone for bladder cancer treatment, but the development of resistance remains a major clinical challenge. Curcumol, a bioactive sesquiterpenoid derived from , has shown anti-tumor potential. This study investigated the efficacy of curcumol in overcoming cisplatin resistance and elucidated its underlying molecular mechanisms in bladder cancer progression. - Source: PubMed
Zhang FacaiYang YunkaiZhang RongHu HuanZhou ChuanzanWang JieWu RuichengLi EnhuiCho William CZhang DahongZhang QiFeng Dechao - DNA replication initiation is a tightly regulated process that requires the coordinated assembly of replication machineries throughout the genome. During the first step of initiation, origin licensing, the MCM replicative helicase motor is loaded onto replication origins by the origin recognition complex (ORC) as a head-to-head double hexamer complex. Distinct mechanisms have been proposed to facilitate human MCM double hexamer loading, but the physiological relevance of each of them remains unclear. Here, we investigate the evolutionary conservation of these pathways using an AlphaFold-guided structural phylogenetics approach. Our analyses reveal that ORC6, a subunit of ORC previously thought to be essential for origin licensing in vivo, has been lost in multiple metazoan lineages. Despite this loss, many of these species retain an element in ORC3, the ORC3 tether, that can interact with MCM and facilitate an ORC6-independent MCM loading mechanism. AlphaFold2 Multimer predictions suggest that ORC3 tether interactions with MCM are broadly conserved across Metazoa. Our findings support the physiological relevance of ORC6-independent MCM loading, provide experimentally testable hypotheses on origin licensing mechanisms in diverse metazoan species, and highlight how AlphaFold can be leveraged to investigate protein evolution and function over large timescales. - Source: PubMed
Publication date: 2025/11/27
Hunker OliviaBleichert Franziska - Precision therapy for glioma remains a major challenge due to tumor heterogeneity. The Origin Recognition Complex Subunit 6 (ORC6) is a crucial regulator of DNA replication initiation. This study aims to investigate the expression of ORC6 in gliomas and its relationship with survival rates and malignancy, while screening potential drugs targeting its functional network. By integrating multiple bioinformatics approaches with structure-based virtual screening, retrospective RNA sequencing data analysis was performed using patients from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) databases. A protein-protein interaction (PPI) network was constructed from ORC6-coexpressed genes to identify core hubs. Molecular docking was employed to screen a library of natural compounds and known drugs against these hub targets. Research has revealed that ORC6 is significantly upregulated in high-grade gliomas, with its elevated expression associated with poor survival outcomes and immune inflammatory responses. Network analysis identified five core hub genes (ORC1, ORC2, MCM2, MCM6, CDC45) central to DNA replication. Molecular docking revealed that several compounds, including the natural flavonoid Baicalein and the FDA-approved drug Palbociclib, exhibited high binding affinity to these hub targets. ORC6 represents a highly promising novel target for precision therapy in glioma. Potential approaches to target this pathway include disrupting the ORC6-replication axis using existing drugs (such as palbociclib) or natural products (such as baicalin). - Source: PubMed
Publication date: 2025/11/19
Wang MengjieFeng SongZhang ChenJin Feng